Pharmala Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for Ala-002 MDMA Therapy (mdxxf)
PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF) The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing PharmAla to retain internatio